S&P 500   3,304.27 (-1.57%)
DOW   27,606.39 (-1.06%)
QQQ   264.61 (-2.11%)
AAPL   106.92 (-3.10%)
MSFT   197.94 (-2.45%)
FB   251.85 (-1.17%)
GOOGL   1,442.00 (-3.03%)
AMZN   2,931.03 (-2.58%)
NVDA   484.00 (-2.92%)
TSLA   436.04 (+2.98%)
BABA   271.75 (-1.44%)
CGC   16.38 (-0.12%)
GE   6.97 (-1.13%)
MU   50.41 (-1.12%)
AMD   74.42 (-2.78%)
T   29.04 (-0.10%)
F   7.29 (+0.14%)
ACB   6.51 (-5.52%)
GILD   64.39 (-1.00%)
NFLX   463.21 (-1.49%)
DIS   129.30 (-0.71%)
BAC   25.43 (+0.32%)
BA   163.70 (-2.29%)
S&P 500   3,304.27 (-1.57%)
DOW   27,606.39 (-1.06%)
QQQ   264.61 (-2.11%)
AAPL   106.92 (-3.10%)
MSFT   197.94 (-2.45%)
FB   251.85 (-1.17%)
GOOGL   1,442.00 (-3.03%)
AMZN   2,931.03 (-2.58%)
NVDA   484.00 (-2.92%)
TSLA   436.04 (+2.98%)
BABA   271.75 (-1.44%)
CGC   16.38 (-0.12%)
GE   6.97 (-1.13%)
MU   50.41 (-1.12%)
AMD   74.42 (-2.78%)
T   29.04 (-0.10%)
F   7.29 (+0.14%)
ACB   6.51 (-5.52%)
GILD   64.39 (-1.00%)
NFLX   463.21 (-1.49%)
DIS   129.30 (-0.71%)
BAC   25.43 (+0.32%)
BA   163.70 (-2.29%)
S&P 500   3,304.27 (-1.57%)
DOW   27,606.39 (-1.06%)
QQQ   264.61 (-2.11%)
AAPL   106.92 (-3.10%)
MSFT   197.94 (-2.45%)
FB   251.85 (-1.17%)
GOOGL   1,442.00 (-3.03%)
AMZN   2,931.03 (-2.58%)
NVDA   484.00 (-2.92%)
TSLA   436.04 (+2.98%)
BABA   271.75 (-1.44%)
CGC   16.38 (-0.12%)
GE   6.97 (-1.13%)
MU   50.41 (-1.12%)
AMD   74.42 (-2.78%)
T   29.04 (-0.10%)
F   7.29 (+0.14%)
ACB   6.51 (-5.52%)
GILD   64.39 (-1.00%)
NFLX   463.21 (-1.49%)
DIS   129.30 (-0.71%)
BAC   25.43 (+0.32%)
BA   163.70 (-2.29%)
S&P 500   3,304.27 (-1.57%)
DOW   27,606.39 (-1.06%)
QQQ   264.61 (-2.11%)
AAPL   106.92 (-3.10%)
MSFT   197.94 (-2.45%)
FB   251.85 (-1.17%)
GOOGL   1,442.00 (-3.03%)
AMZN   2,931.03 (-2.58%)
NVDA   484.00 (-2.92%)
TSLA   436.04 (+2.98%)
BABA   271.75 (-1.44%)
CGC   16.38 (-0.12%)
GE   6.97 (-1.13%)
MU   50.41 (-1.12%)
AMD   74.42 (-2.78%)
T   29.04 (-0.10%)
F   7.29 (+0.14%)
ACB   6.51 (-5.52%)
GILD   64.39 (-1.00%)
NFLX   463.21 (-1.49%)
DIS   129.30 (-0.71%)
BAC   25.43 (+0.32%)
BA   163.70 (-2.29%)
Log in
NASDAQ:ADMS

Adamas Pharmaceuticals Stock Forecast, Price & News

$4.73
+0.12 (+2.60 %)
(As of 09/18/2020 12:34 PM ET)
Add
Compare
Today's Range
$4.57
Now: $4.73
$4.78
50-Day Range
$2.48
MA: $4.39
$5.43
52-Week Range
$1.90
Now: $4.73
$7.78
Volume6,169 shs
Average Volume486,064 shs
Market Capitalization$133.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.29
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Read More
Adamas Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.64 million
Book Value($0.03) per share

Profitability

Net Income$-105,190,000.00
Net Margins-122.52%

Miscellaneous

Employees159
Market Cap$133.77 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$4.73
+0.12 (+2.60 %)
(As of 09/18/2020 12:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

How has Adamas Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMS shares have increased by 54.4% and is now trading at $4.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Adamas Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Adamas Pharmaceuticals
.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Adamas Pharmaceuticals
.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.24. The specialty pharmaceutical company earned $18.79 million during the quarter, compared to analyst estimates of $15.63 million. Adamas Pharmaceuticals had a negative net margin of 122.52% and a negative return on equity of 806.54%.
View Adamas Pharmaceuticals' earnings history
.

What price target have analysts set for ADMS?

8 Wall Street analysts have issued twelve-month price targets for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $16.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $9.10 in the next year. This suggests a possible upside of 93.2% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals
.

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 855,400 shares, a drop of 17.8% from the August 15th total of 1,040,000 shares. Based on an average daily volume of 591,700 shares, the short-interest ratio is presently 1.4 days. Approximately 3.8% of the company's shares are short sold.
View Adamas Pharmaceuticals' Short Interest
.

Who are some of Adamas Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Amarin (AMRN), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX) and Exelixis (EXEL).

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
  • Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
  • Ashleigh Barreto, Director of Corp. Communications & Investor Relations
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Opaleye Management Inc. (3.39%), Assenagon Asset Management S.A. (2.67%), Emerald Advisers LLC (2.38%), Emerald Mutual Fund Advisers Trust (2.21%), AQR Capital Management LLC (1.49%) and Nuveen Asset Management LLC (1.30%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes.
View institutional ownership trends for Adamas Pharmaceuticals
.

Which major investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Deltec Asset Management LLC, Jacobs Levy Equity Management Inc., and SG Americas Securities LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, and Christopher B Prentiss.
View insider buying and selling activity for Adamas Pharmaceuticals
.

Which major investors are buying Adamas Pharmaceuticals stock?

ADMS stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Assenagon Asset Management S.A., AQR Capital Management LLC, Jane Street Group LLC, Bridgeway Capital Management Inc., Worth Venture Partners LLC, Emerald Advisers LLC, and Emerald Mutual Fund Advisers Trust.
View insider buying and selling activity for Adamas Pharmaceuticals
.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $4.71.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $133.21 million and generates $54.64 million in revenue each year. The specialty pharmaceutical company earns $-105,190,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.